Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects...
Saved in:
| Published in | Cell reports (Cambridge) Vol. 36; no. 2; p. 109353 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
13.07.2021
Elsevier Cell Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2211-1247 2211-1247 |
| DOI | 10.1016/j.celrep.2021.109353 |
Cover
Loading…
| Abstract | SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.
[Display omitted]
•Fourteen anti-SARS-CoV-2 neutralizing mAbs isolated from four patients•Three anti-RBD and one anti-S2 mAb neutralized SARS-CoV-1 and the B.1.351 variant•Mouse studies show potential protective effect of anti-NTD mAbs
Jennewein et al. isolated 14 anti-SARS-CoV-2 neutralizing antibodies—one anti-S2, one anti-NTD, and 11 anti-RBD—from four patients. Three anti-RBD and the anti-S2 nAbs cross-neutralized SARS-CoV-1 and B.1.351. The anti-NTD mAbs conferred partial protection in mice. Evolved anti-S2 Abs may provide templates for pan-coronavirus vaccines. |
|---|---|
| AbstractList | SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the
in vivo
protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.
•
Fourteen anti-SARS-CoV-2 neutralizing mAbs isolated from four patients
•
Three anti-RBD and one anti-S2 mAb neutralized SARS-CoV-1 and the B.1.351 variant
•
Mouse studies show potential protective effect of anti-NTD mAbs
Jennewein et al. isolated 14 anti-SARS-CoV-2 neutralizing antibodies—one anti-S2, one anti-NTD, and 11 anti-RBD—from four patients. Three anti-RBD and the anti-S2 nAbs cross-neutralized SARS-CoV-1 and B.1.351. The anti-NTD mAbs conferred partial protection in mice. Evolved anti-S2 Abs may provide templates for pan-coronavirus vaccines. SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies. SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies. SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies. [Display omitted] •Fourteen anti-SARS-CoV-2 neutralizing mAbs isolated from four patients•Three anti-RBD and one anti-S2 mAb neutralized SARS-CoV-1 and the B.1.351 variant•Mouse studies show potential protective effect of anti-NTD mAbs Jennewein et al. isolated 14 anti-SARS-CoV-2 neutralizing antibodies—one anti-S2, one anti-NTD, and 11 anti-RBD—from four patients. Three anti-RBD and the anti-S2 nAbs cross-neutralized SARS-CoV-1 and B.1.351. The anti-NTD mAbs conferred partial protection in mice. Evolved anti-S2 Abs may provide templates for pan-coronavirus vaccines. |
| ArticleNumber | 109353 |
| Author | Edara, Venkata Viswanadh Vanderheiden, Abigail Yang, Eun Sung Suthar, Mehul S. Wan, Yu-Hsin Whaley, Rachael E. Stuart, Andrew B. Pancera, Marie MacCamy, Anna J. Ozorowski, Gabriel McGuire, Andrew T. Stamatatos, Leonidas Akins, Nicholas R. Seydoux, Emilie Chu, Helen Y. Wang, Lingshu Homad, Leah J. Mascola, John R. Jennewein, Madeleine F. Feng, Junli Englund, Janet A. Hurlburt, Nicholas K. Doria-Rose, Nicole Cohen, Kristen W. Finzi, Andrés Torres, Jonathan L. Ward, Andrew B. McElrath, M. Juliana Floyd, Katharine |
| Author_xml | – sequence: 1 givenname: Madeleine F. surname: Jennewein fullname: Jennewein, Madeleine F. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 2 givenname: Anna J. surname: MacCamy fullname: MacCamy, Anna J. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 3 givenname: Nicholas R. surname: Akins fullname: Akins, Nicholas R. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 4 givenname: Junli surname: Feng fullname: Feng, Junli organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 5 givenname: Leah J. surname: Homad fullname: Homad, Leah J. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 6 givenname: Nicholas K. surname: Hurlburt fullname: Hurlburt, Nicholas K. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 7 givenname: Emilie surname: Seydoux fullname: Seydoux, Emilie organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 8 givenname: Yu-Hsin surname: Wan fullname: Wan, Yu-Hsin organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 9 givenname: Andrew B. surname: Stuart fullname: Stuart, Andrew B. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 10 givenname: Venkata Viswanadh surname: Edara fullname: Edara, Venkata Viswanadh organization: Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30322, USA – sequence: 11 givenname: Katharine surname: Floyd fullname: Floyd, Katharine organization: Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30322, USA – sequence: 12 givenname: Abigail surname: Vanderheiden fullname: Vanderheiden, Abigail organization: Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30322, USA – sequence: 13 givenname: John R. surname: Mascola fullname: Mascola, John R. organization: Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA – sequence: 14 givenname: Nicole surname: Doria-Rose fullname: Doria-Rose, Nicole organization: Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA – sequence: 15 givenname: Lingshu surname: Wang fullname: Wang, Lingshu organization: Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA – sequence: 16 givenname: Eun Sung surname: Yang fullname: Yang, Eun Sung organization: Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA – sequence: 17 givenname: Helen Y. surname: Chu fullname: Chu, Helen Y. organization: University of Washington, Department of Medicine, Seattle, WA 98109, USA – sequence: 18 givenname: Jonathan L. surname: Torres fullname: Torres, Jonathan L. organization: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA – sequence: 19 givenname: Gabriel surname: Ozorowski fullname: Ozorowski, Gabriel organization: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA – sequence: 20 givenname: Andrew B. surname: Ward fullname: Ward, Andrew B. organization: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA – sequence: 21 givenname: Rachael E. surname: Whaley fullname: Whaley, Rachael E. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 22 givenname: Kristen W. surname: Cohen fullname: Cohen, Kristen W. organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 23 givenname: Marie surname: Pancera fullname: Pancera, Marie organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 24 givenname: M. Juliana surname: McElrath fullname: McElrath, M. Juliana organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 25 givenname: Janet A. surname: Englund fullname: Englund, Janet A. organization: Department of Pediatrics, University of Washington and Seattle Children’s Research Institute, Seattle, WA 98109, USA – sequence: 26 givenname: Andrés surname: Finzi fullname: Finzi, Andrés organization: Université de Montréal, Montreal, QC, Canada – sequence: 27 givenname: Mehul S. surname: Suthar fullname: Suthar, Mehul S. email: mehul.s.suthar@emory.edu organization: Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30322, USA – sequence: 28 givenname: Andrew T. surname: McGuire fullname: McGuire, Andrew T. email: amcguire@fredhutch.org organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA – sequence: 29 givenname: Leonidas surname: Stamatatos fullname: Stamatatos, Leonidas email: lstamata@fredhutch.org organization: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Disease Division, Seattle, WA 98109, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34237283$$D View this record in MEDLINE/PubMed https://www.osti.gov/servlets/purl/1815023$$D View this record in Osti.gov |
| BookMark | eNqFUk1v1DAUjFARLaX_AKGIExLK4q84MYdKaPlaqVIvwNVy7Jddr7L2Yjsr0V-Ps1mqlgP4Yut53njG854XZ847KIqXGC0wwvzddqFhCLBfEERwLgla0yfFBSEYV5iw5uzB-by4inGL8uIIY8GeFeeUEdqQll4UehX9oJL1rlTOlHqjgtIJgr2bi74vdfAxVg7GFNRg76xbl9oH79TBhjHmtmQ7byzEsg9-Vy5vf6w-Vli8LePYbUGn-KJ42qshwtVpvyy-f_70bfm1urn9slp-uKk0JyRVRkGvNcGaNV1NmyzVtJwzjFCLaMeJ6KDhQIQihAkhOGIGc8OpwjUCAoReFquZ13i1lftgdyr8kl5ZeSz4sJYqJKsHkD0TxHQagxA1E7RVDbSc1IYBNprXkLmuZ6792O3AaHCT-0ekj2-c3ci1P8iWYN6yJhO8ngl8TFZGbRPojfbO5R-RuM2aCc2gN6dXgv85QkxyZ2NOdlAO_BglqTOMowZN0FcPBd0r-RNlBrAZcMwrQH8PwUhOQyO3ch4aOQ2NnIcmt73_qy1LPWafbdnhf82nX4Ic68FCmIyC02BsmHwab_9N8BtIYt6r |
| CitedBy_id | crossref_primary_10_1016_j_virol_2022_08_010 crossref_primary_10_1093_cid_ciac057 crossref_primary_10_1371_journal_ppat_1010981 crossref_primary_10_1016_j_isci_2022_104528 crossref_primary_10_1016_j_chom_2021_12_004 crossref_primary_10_1038_s41590_022_01222_1 crossref_primary_10_1080_08820139_2022_2092407 crossref_primary_10_1111_febs_16777 crossref_primary_10_3390_v15091926 crossref_primary_10_1016_j_xcrm_2022_100603 crossref_primary_10_1038_s41467_023_36295_5 crossref_primary_10_1080_22221751_2023_2220582 crossref_primary_10_1128_mbio_00907_24 crossref_primary_10_1111_imr_13431 crossref_primary_10_1016_j_celrep_2022_110368 crossref_primary_10_1007_s00281_023_00996_2 crossref_primary_10_1371_journal_ppat_1010691 crossref_primary_10_1172_jci_insight_157597 crossref_primary_10_1016_j_immuni_2021_08_015 crossref_primary_10_1080_22221751_2021_2024455 crossref_primary_10_1128_jvi_00531_24 crossref_primary_10_1128_spectrum_01814_21 crossref_primary_10_1038_s42003_022_03262_7 crossref_primary_10_2139_ssrn_4147939 crossref_primary_10_1016_j_xpro_2021_100851 crossref_primary_10_4103_abr_abr_195_22 crossref_primary_10_1038_s41541_023_00633_x crossref_primary_10_1126_scitranslmed_abo2847 crossref_primary_10_1016_j_isci_2022_105783 crossref_primary_10_1016_j_immuni_2021_08_024 crossref_primary_10_1038_s41564_022_01268_9 crossref_primary_10_3390_v16060900 crossref_primary_10_1146_annurev_med_042420_113838 crossref_primary_10_1016_j_ebiom_2022_104341 crossref_primary_10_1038_s41598_023_43661_2 crossref_primary_10_1016_j_celrep_2023_111998 crossref_primary_10_1073_pnas_2220948120 crossref_primary_10_1038_s41541_023_00755_2 crossref_primary_10_3390_vaccines11020242 crossref_primary_10_1016_j_immuni_2023_02_005 crossref_primary_10_3390_v15102004 crossref_primary_10_1038_s41598_024_53117_w crossref_primary_10_1126_science_adn5658 crossref_primary_10_1371_journal_ppat_1012383 crossref_primary_10_1016_j_biopha_2024_116900 crossref_primary_10_1248_bpb_b23_00639 crossref_primary_10_3389_fmedt_2022_867982 crossref_primary_10_1016_j_virol_2025_110512 crossref_primary_10_1016_j_isci_2022_105316 crossref_primary_10_1126_sciimmunol_ade0958 crossref_primary_10_3390_ijms222212114 crossref_primary_10_1186_s41232_022_00233_7 crossref_primary_10_1016_j_celrep_2022_110429 crossref_primary_10_1016_j_immuni_2022_04_010 crossref_primary_10_3390_v14010005 crossref_primary_10_1016_j_xcrm_2022_100540 crossref_primary_10_1016_j_celrep_2022_111554 crossref_primary_10_1016_j_coviro_2021_12_015 crossref_primary_10_1016_j_immuni_2022_05_005 crossref_primary_10_1038_s41467_022_35642_2 crossref_primary_10_1371_journal_ppat_1012650 crossref_primary_10_1016_j_virol_2021_09_001 crossref_primary_10_7554_eLife_75433 crossref_primary_10_3390_pharmaceutics15051412 crossref_primary_10_3390_v15061274 crossref_primary_10_15789_2220_7619_IAF_1998 crossref_primary_10_1016_j_jbc_2021_101151 crossref_primary_10_1016_j_isci_2022_104990 crossref_primary_10_1016_j_isci_2024_109363 crossref_primary_10_1080_21645515_2022_2055373 crossref_primary_10_1016_j_celrep_2021_110210 crossref_primary_10_1016_j_virol_2025_110467 crossref_primary_10_1111_imr_13084 crossref_primary_10_1016_j_xcrm_2022_100893 |
| Cites_doi | 10.1128/JVI.00127-20 10.1016/j.chom.2021.03.005 10.1128/JVI.00985-20 10.1056/NEJMoa2022483 10.1107/S0021889807021206 10.1056/NEJMoa2027906 10.1038/s41467-020-19231-9 10.1126/science.abb2507 10.1016/j.cell.2021.03.028 10.1126/science.abc6284 10.1016/j.celrep.2020.107918 10.1038/s41586-020-2456-9 10.1016/j.cell.2020.05.025 10.1038/s41586-020-2548-6 10.1016/j.cell.2020.08.046 10.1084/jem.20201993 10.1038/s41586-020-2380-z 10.1016/S0140-6736(21)00183-5 10.1093/nar/gkn316 10.1016/j.antiviral.2020.104820 10.1128/JVI.01118-06 10.1126/science.abc5902 10.1126/science.abc6952 10.1107/S0907444909047337 10.1038/s41586-020-2571-7 10.1126/science.abc2241 10.1016/j.cell.2020.02.058 10.1016/j.jsb.2009.01.002 10.3390/v13010134 10.1126/science.abc7424 10.1038/s41586-020-2381-y 10.1126/science.abe2402 10.1038/s41586-020-2607-z 10.1016/j.cell.2020.09.033 10.1056/NEJMc2102017 10.1016/j.jsb.2005.03.010 10.1016/j.jsb.2012.09.006 10.1126/science.abd0831 10.1038/s41590-020-0778-2 10.1107/S0909049503024130 10.15585/mmwr.mm6905e1 10.1038/s41591-021-01285-x 10.1107/S0907444904019158 10.1126/science.abd0826 10.1126/science.abe6230 10.1016/j.cell.2020.04.031 10.1016/S1473-3099(20)30120-1 10.3390/v12050513 10.1073/pnas.93.21.11382 10.1016/j.cell.2020.06.025 10.1038/nature09385 10.1073/pnas.1707304114 10.1016/j.chom.2020.04.004 10.1016/j.cell.2020.02.052 10.1016/j.jim.2007.09.017 10.1038/s41586-021-03207-w 10.1126/science.abd4251 10.1073/pnas.1217207109 10.1016/j.it.2020.09.004 10.1038/s41586-020-2349-y 10.1126/science.abc7520 10.1016/j.immuni.2020.06.001 10.1126/science.abe3354 10.1016/j.chom.2020.09.002 10.1126/science.abg9175 10.1056/NEJMc2102179 10.1038/s41467-020-16256-y 10.1016/j.jsb.2009.01.004 10.1016/j.celrep.2020.107725 10.1016/j.immuni.2018.03.026 10.1126/science.abb2762 |
| ContentType | Journal Article |
| Copyright | 2021 The Author(s) Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. 2021 The Author(s) 2021 |
| Copyright_xml | – notice: 2021 The Author(s) – notice: Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. – notice: 2021 The Author(s) 2021 |
| CorporateAuthor | Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
| CorporateAuthor_xml | – name: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 OIOZB OTOTI 5PM DOA |
| DOI | 10.1016/j.celrep.2021.109353 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic OSTI.GOV - Hybrid OSTI.GOV PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (WRLC) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2211-1247 |
| ExternalDocumentID | oai_doaj_org_article_f492dbc1e9954938a7e8625d4e1dc65e PMC8216847 1815023 34237283 10_1016_j_celrep_2021_109353 S2211124721007294 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIH HHS grantid: P51 OD011132 – fundername: NIAID NIH HHS grantid: U19 AI057266 |
| GroupedDBID | 0R~ 0SF 4.4 457 53G 5VS 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AAKRW AALRI AAUCE AAXUO ABMAC ABMWF ACGFO ACGFS ADBBV ADEZE AENEX AEXQZ AFTJW AGHFR AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV DIK EBS EJD FCP FDB FRP GROUPED_DOAJ GX1 IXB KQ8 M41 M48 NCXOZ O-L O9- OK1 RCE ROL SSZ AAMRU AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AIGII AKBMS AKRWK AKYEP APXCP CITATION HZ~ IPNFZ RIG CGR CUY CVF ECM EIF NPM 7X8 OIOZB OTOTI 5PM |
| ID | FETCH-LOGICAL-c622t-daefcc21c47b537119d8664100803b629be76e29a224999604d16d63a150e2e23 |
| IEDL.DBID | M48 |
| ISSN | 2211-1247 |
| IngestDate | Wed Aug 27 01:28:47 EDT 2025 Thu Aug 21 18:07:02 EDT 2025 Fri May 19 01:41:22 EDT 2023 Fri Jul 11 01:48:22 EDT 2025 Mon Jul 21 05:34:52 EDT 2025 Thu Apr 24 23:13:09 EDT 2025 Tue Jul 01 02:59:19 EDT 2025 Tue Jul 25 21:00:21 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | S2 subunit SARS-CoV-2 SARS-CoV-1 B.1.351 RBD neutralization CV3-25 NTD monoclonal antibodies |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c622t-daefcc21c47b537119d8664100803b629be76e29a224999604d16d63a150e2e23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Ministry of Economy, Innovation and Energy, Canada USDOE Office of Science (SC) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) AC02-06CH11357; P51 OD011132; 3U19AI057266-17S1; OPP1170236/INV-004923; 352417; RCHS0235 950-232424 Fred Hutch COVID-19 Research Fund Bill and Melinda Gates Foundation Club Foundation Fondation du CHUM Lead contact |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.celrep.2021.109353 |
| PMID | 34237283 |
| PQID | 2550260703 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f492dbc1e9954938a7e8625d4e1dc65e pubmedcentral_primary_oai_pubmedcentral_nih_gov_8216847 osti_scitechconnect_1815023 proquest_miscellaneous_2550260703 pubmed_primary_34237283 crossref_primary_10_1016_j_celrep_2021_109353 crossref_citationtrail_10_1016_j_celrep_2021_109353 elsevier_sciencedirect_doi_10_1016_j_celrep_2021_109353 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-13 |
| PublicationDateYYYYMMDD | 2021-07-13 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cell reports (Cambridge) |
| PublicationTitleAlternate | Cell Rep |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc Elsevier Cell Press |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: Cell Press |
| References | Tai, Zhang, He, Jiang, Du (bib57) 2020; 179 Vanderheiden, Ralfs, Chirkova, Upadhyay, Zimmerman, Bedoya, Aoued, Tharp, Pellegrini, Manfredi (bib61) 2020; 94 Tiller, Meffre, Yurasov, Tsuiji, Nussenzweig, Wardemann (bib59) 2008; 329 Liu, Liu, Xia, Zhang, Fontes-Garfias, Swanson, Cai, Sarkar, Chen, Cutler (bib32) 2021; 384 Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman, Lockhart, Neuzil, Mulligan, Bailey (bib65) 2020; 383 Gavor, Choong, Er, Sivaraman, Sivaraman (bib21) 2020; 41 Wibmer, Ayres, Hermanus, Madzivhandila, Kgagudi, Oosthuysen, Lambson, de Oliveira, Vermeulen, van der Berg (bib72) 2021; 27 Sabino, Buss, Carvalho, Prete, Crispim, Fraiji, Pereira, Parag, da Silva Peixoto, Kraemer (bib47) 2021; 397 Suloway, Pulokas, Fellmann, Cheng, Guerra, Quispe, Stagg, Potter, Carragher (bib56) 2005; 151 Gaebler, Wang, Lorenzi, Muecksch, Finkin, Tokuyama, Cho, Jankovic, Schaefer-Babajew, Oliveira (bib20) 2021; 591 Cerutti, Guo, Zhou, Gorman, Lee, Rapp, Reddem, Yu, Bahna, Bimela (bib10) 2021; 29 Robbiani, Gaebler, Muecksch, Lorenzi, Wang, Cho, Agudelo, Barnes, Gazumyan, Finkin (bib45) 2020; 584 Zost, Gilchuk, Case, Binshtein, Chen, Nkolola, Schäfer, Reidy, Trivette, Nargi (bib81) 2020; 584 Adams, Gopal, Grosse-Kunstleve, Hung, Ioerger, McCoy, Moriarty, Pai, Read, Romo (bib1) 2004; 11 Scheres (bib49) 2012; 180 Dong, Du, Gardner (bib15) 2020; 20 Nielsen, Yang, Jackson, Hoh, Röltgen, Jean, Stevens, Lee, Rustagi, Rogers (bib39) 2020; 28 Wan, Shang, Graham, Baric, Li (bib67) 2020; 94 Hurlburt, Seydoux, Wan, Edara, Stuart, Feng, Suthar, McGuire, Stamatatos, Pancera (bib24) 2020; 11 Wrapp, Wang, Corbett, Goldsmith, Hsieh, Abiona, Graham, McLellan (bib75) 2020; 367 Liu, Wang, Nair, Yu, Rapp, Wang, Luo, Chan, Sahi, Figueroa (bib31) 2020; 584 Tegally, Wilkinson, Giovanetti, Iranzadeh, Fonseca, Giandhari, Doolabh, Pillay, San, Msomi (bib58) 2020 Schäfer, Muecksch, Lorenzi, Leist, Cipolla, Bournazos, Schmidt, Maison, Gazumyan, Martinez (bib48) 2021; 218 Pallesen, Wang, Corbett, Wrapp, Kirchdoerfer, Turner, Cottrell, Becker, Wang, Shi (bib41) 2017; 114 Rogers, Zhao, Huang, Beutler, Burns, He, Limbo, Smith, Song, Woehl (bib46) 2020; 369 Volz, Mishra, Chand, Barrett, Johnson, Geidelberg, Hinsley, Laydon, Dabrera, O’Toole (bib62) 2021 Wan, Xing, Ding, Wang, Gu, Wu, Rong, Li, Wang, Chen (bib66) 2020; 32 Kabsch (bib27) 2010; 66 Lv, Wu, Tsang, Yuan, Perera, Leung, So, Chan, Yip, Chik (bib33) 2020; 31 Hsieh, Goldsmith, Schaub, DiVenere, Kuo, Javanmardi, Le, Wrapp, Lee, Liu (bib23) 2020; 369 Wang, Li, Drabek, Okba, van Haperen, Osterhaus, van Kuppeveld, Haagmans, Grosveld, Bosch (bib68) 2020; 11 Wec, Wrapp, Herbert, Maurer, Haslwanter, Sakharkar, Jangra, Dieterle, Lilov, Huang (bib70) 2020; 369 Cao, Su, Guo, Sun, Deng, Bao, Zhu, Zhang, Zheng, Geng (bib9) 2020; 182 Patel, Jernigan (bib42) 2020; 69 Wang, van Haperen, Gutiérrez-Álvarez, Li, Okba, Albulescu, Widjaja, van Dieren, Fernandez-Delgado, Sola (bib69) 2020 Song, He, Callaghan, Anzanello, Huang, Ricketts, Torres, Beutler, Peng, Vargas (bib53) 2020 Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler, Erichsen, Schiergens, Herrler, Wu, Nitsche (bib22) 2020; 181 Rambaut, Loman, Pybus, Barclay, Barrett, Carabelli, Connor, Peacock, Robertson, Volz (bib44) 2020 Mouquet, Scharf, Euler, Liu, Eden, Scheid, Halper-Stromberg, Gnanapragasam, Spencer, Seaman (bib37) 2012; 109 Yu, Tostanoski, Peter, Mercado, McMahan, Mahrokhian, Nkolola, Liu, Li, Chandrashekar (bib80) 2020; 369 Stamatatos, Czartoski, Wan, Homad, Rubin, Glantz, Neradilek, Seydoux, Jennewein, MacCamy (bib55) 25 Jun 2021; 372 Baum, Ajithdoss, Copin, Zhou, Lanza, Negron, Ni, Wei, Mohammadi, Musser (bib3) 2020; 370 Naldini, Blömer, Gage, Trono, Verma (bib38) 1996; 93 Walls, Park, Tortorici, Wall, McGuire, Veesler (bib64) 2020; 181 Barnes, West, Huey-Tubman, Hoffmann, Sharaf, Hoffman, Koranda, Gristick, Gaebler, Muecksch (bib2) 2020; 182 Tortorici, Beltramello, Lempp, Pinto, Dang, Rosen, McCallum, Bowen, Minola, Jaconi (bib60) 2020; 370 Yan, Zhang, Li, Xia, Guo, Zhou (bib79) 2020; 367 Lander, Stagg, Voss, Cheng, Fellmann, Pulokas, Yoshioka, Irving, Mulder, Lau (bib30) 2009; 166 Böttcher, Matrosovich, Beyerle, Klenk, Garten, Matrosovich (bib5) 2006; 80 Clausen, Sandoval, Spliid, Pihl, Perrett, Painter, Narayanan, Majowicz, Kwong, McVicar (bib12) 2020; 183 McCallum, De Marco, Lempp, Tortorici, Pinto, Walls, Beltramello, Chen, Liu, Zatta (bib34) 2021; 184 Weinreich, Sivapalasingam, Norton, Ali, Gao, Bhore, Musser, Soo, Rofail, Im (bib71) 2020; 384 Davies, Barnard, Jarvis, Kucharski, Munday, Pearson, Russell, Tully, Abbott, Gimma (bib14) 2020 Winkler, Bailey, Kafai, Nair, McCune, Yu, Fox, Chen, Earnest, Keeler (bib73) 2020; 21 Wu, Werner, Koch, Choi, Narayanan, Stewart-Jones, Colpitts, Bennett, Boyoglu-Barnum, Shi (bib77) 2021; 384 Koenig, Das, Liu, Kümmerer, Gohr, Jenster, Schiffelers, Tesfamariam, Uchima, Wuerth (bib28) 2021; 371 Wrapp, De Vlieger, Corbett, Torres, Wang, Van Breedam, Roose, van Schie, Hoffmann, Pöhlmann (bib74) 2020; 181 Mouquet, Scheid, Zoller, Krogsgaard, Ott, Shukair, Artyomov, Pietzsch, Connors, Pereyra (bib82) 2010; 467 Brouwer, Caniels, van der Straten, Snitselaar, Aldon, Bangaru, Torres, Okba, Claireaux, Kerster (bib7) 2020; 369 O’Toole, Hill, Pybus, Watts, Bogoch, Khan, Messina, Tegally, Lessells, Giandhari, Pillay (bib40) 2021 Crawford, Eguia, Dingens, Loes, Malone, Wolf, Chu, Tortorici, Veesler, Murphy (bib13) 2020; 12 Kreer, Zehner, Weber, Ercanoglu, Gieselmann, Rohde, Halwe, Korenkov, Schommers, Vanshylla (bib29) 2020; 182 Faria, Claro, Candido, Franco, Andrade, Coletti, Silva, Sales, Manuli, Aguiar (bib18) 2021 Mercado, Zahn, Wegmann, Loos, Chandrashekar, Yu, Liu, Peter, McMahan, Tostanoski (bib36) 2020; 586 Finkelstein, Mermelstein, Parker Miller, Seth, Stancofski, Fera (bib19) 2021; 13 Snijder, Ortego, Weidle, Stuart, Gray, McElrath, Pancera, Veesler, McGuire (bib52) 2018; 48 Seydoux, Homad, MacCamy, Parks, Hurlburt, Jennewein, Akins, Stuart, Wan, Feng (bib50) 2020; 53 Xie, Muruato, Lokugamage, Narayanan, Zhang, Zou, Liu, Schindewolf, Bopp, Aguilar (bib78) 2020; 27 Edara, Floyd, Lai, Gardner, Hudson, Piantadosi, Waggoner, Babiker, Ahmed, Xie (bib16) 2021 Wu, Wang, Shen, Peng, Li, Zhao, Li, Li, Bi, Yang (bib76) 2020; 368 Jackson, Anderson, Rouphael, Roberts, Makhene, Coler, McCullough, Chappell, Denison, Stevens (bib25) 2020; 383 McCoy, Grosse-Kunstleve, Adams, Winn, Storoni, Read (bib35) 2007; 40 Chi, Yan, Zhang, Zhang, Zhang, Hao, Zhang, Fan, Dong, Yang (bib11) 2020; 369 Shi, Shan, Duan, Chen, Liu, Song, Song, Bi, Han, Wu (bib51) 2020; 584 Brochet, Lefranc, Giudicelli (bib6) 2008; 36 Ju, Zhang, Ge, Wang, Sun, Ge, Yu, Shan, Zhou, Song (bib26) 2020; 584 Voss, Yoshioka, Radermacher, Potter, Carragher (bib63) 2009; 166 Cai, Zhang, Xiao, Peng, Sterling, Walsh, Rawson, Rits-Volloch, Chen (bib8) 2020; 369 Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco (bib43) 2020; 583 Baum, Fulton, Wloga, Copin, Pascal, Russo, Giordano, Lanza, Negron, Ni (bib4) 2020; 369 Emsley, Cowtan (bib17) 2004; 60 Weinreich (10.1016/j.celrep.2021.109353_bib71) 2020; 384 Wu (10.1016/j.celrep.2021.109353_bib76) 2020; 368 Edara (10.1016/j.celrep.2021.109353_bib16) 2021 Mouquet (10.1016/j.celrep.2021.109353_bib82) 2010; 467 Tai (10.1016/j.celrep.2021.109353_bib57) 2020; 179 Brochet (10.1016/j.celrep.2021.109353_bib6) 2008; 36 Gavor (10.1016/j.celrep.2021.109353_bib21) 2020; 41 Yan (10.1016/j.celrep.2021.109353_bib79) 2020; 367 Naldini (10.1016/j.celrep.2021.109353_bib38) 1996; 93 Stamatatos (10.1016/j.celrep.2021.109353_bib55) 2021; 372 Tiller (10.1016/j.celrep.2021.109353_bib59) 2008; 329 Cao (10.1016/j.celrep.2021.109353_bib9) 2020; 182 Davies (10.1016/j.celrep.2021.109353_bib14) 2020 Schäfer (10.1016/j.celrep.2021.109353_bib48) 2021; 218 Brouwer (10.1016/j.celrep.2021.109353_bib7) 2020; 369 Robbiani (10.1016/j.celrep.2021.109353_bib45) 2020; 584 Nielsen (10.1016/j.celrep.2021.109353_bib39) 2020; 28 Yu (10.1016/j.celrep.2021.109353_bib80) 2020; 369 Liu (10.1016/j.celrep.2021.109353_bib31) 2020; 584 O’Toole (10.1016/j.celrep.2021.109353_bib40) 2021 Winkler (10.1016/j.celrep.2021.109353_bib73) 2020; 21 Zost (10.1016/j.celrep.2021.109353_bib81) 2020; 584 Lv (10.1016/j.celrep.2021.109353_bib33) 2020; 31 Pallesen (10.1016/j.celrep.2021.109353_bib41) 2017; 114 Shi (10.1016/j.celrep.2021.109353_bib51) 2020; 584 Suloway (10.1016/j.celrep.2021.109353_bib56) 2005; 151 Wang (10.1016/j.celrep.2021.109353_bib69) 2020 Dong (10.1016/j.celrep.2021.109353_bib15) 2020; 20 Scheres (10.1016/j.celrep.2021.109353_bib49) 2012; 180 Wu (10.1016/j.celrep.2021.109353_bib77) 2021; 384 Mercado (10.1016/j.celrep.2021.109353_bib36) 2020; 586 Wang (10.1016/j.celrep.2021.109353_bib68) 2020; 11 Lander (10.1016/j.celrep.2021.109353_bib30) 2009; 166 Cerutti (10.1016/j.celrep.2021.109353_bib10) 2021; 29 Baum (10.1016/j.celrep.2021.109353_bib4) 2020; 369 Koenig (10.1016/j.celrep.2021.109353_bib28) 2021; 371 Wan (10.1016/j.celrep.2021.109353_bib66) 2020; 32 Finkelstein (10.1016/j.celrep.2021.109353_bib19) 2021; 13 Tegally (10.1016/j.celrep.2021.109353_bib58) 2020 Crawford (10.1016/j.celrep.2021.109353_bib13) 2020; 12 Wrapp (10.1016/j.celrep.2021.109353_bib74) 2020; 181 Hoffmann (10.1016/j.celrep.2021.109353_bib22) 2020; 181 Ju (10.1016/j.celrep.2021.109353_bib26) 2020; 584 Wrapp (10.1016/j.celrep.2021.109353_bib75) 2020; 367 Hurlburt (10.1016/j.celrep.2021.109353_bib24) 2020; 11 McCoy (10.1016/j.celrep.2021.109353_bib35) 2007; 40 Pinto (10.1016/j.celrep.2021.109353_bib43) 2020; 583 Walsh (10.1016/j.celrep.2021.109353_bib65) 2020; 383 Seydoux (10.1016/j.celrep.2021.109353_bib50) 2020; 53 Baum (10.1016/j.celrep.2021.109353_bib3) 2020; 370 Liu (10.1016/j.celrep.2021.109353_bib32) 2021; 384 Snijder (10.1016/j.celrep.2021.109353_bib52) 2018; 48 Vanderheiden (10.1016/j.celrep.2021.109353_bib61) 2020; 94 Sabino (10.1016/j.celrep.2021.109353_bib47) 2021; 397 McCallum (10.1016/j.celrep.2021.109353_bib34) 2021; 184 Xie (10.1016/j.celrep.2021.109353_bib78) 2020; 27 Kreer (10.1016/j.celrep.2021.109353_bib29) 2020; 182 Rogers (10.1016/j.celrep.2021.109353_bib46) 2020; 369 Kabsch (10.1016/j.celrep.2021.109353_bib27) 2010; 66 Barnes (10.1016/j.celrep.2021.109353_bib2) 2020; 182 Chi (10.1016/j.celrep.2021.109353_bib11) 2020; 369 Voss (10.1016/j.celrep.2021.109353_bib63) 2009; 166 Clausen (10.1016/j.celrep.2021.109353_bib12) 2020; 183 Walls (10.1016/j.celrep.2021.109353_bib64) 2020; 181 Faria (10.1016/j.celrep.2021.109353_bib18) 2021 Hsieh (10.1016/j.celrep.2021.109353_bib23) 2020; 369 Rambaut (10.1016/j.celrep.2021.109353_bib44) 2020 Wec (10.1016/j.celrep.2021.109353_bib70) 2020; 369 Adams (10.1016/j.celrep.2021.109353_bib1) 2004; 11 Patel (10.1016/j.celrep.2021.109353_bib42) 2020; 69 Wibmer (10.1016/j.celrep.2021.109353_bib72) 2021; 27 Emsley (10.1016/j.celrep.2021.109353_bib17) 2004; 60 Gaebler (10.1016/j.celrep.2021.109353_bib20) 2021; 591 Volz (10.1016/j.celrep.2021.109353_bib62) 2021 Böttcher (10.1016/j.celrep.2021.109353_bib5) 2006; 80 Jackson (10.1016/j.celrep.2021.109353_bib25) 2020; 383 Tortorici (10.1016/j.celrep.2021.109353_bib60) 2020; 370 Song (10.1016/j.celrep.2021.109353_bib53) 2020 Mouquet (10.1016/j.celrep.2021.109353_bib37) 2012; 109 Wan (10.1016/j.celrep.2021.109353_bib67) 2020; 94 Cai (10.1016/j.celrep.2021.109353_bib8) 2020; 369 33791692 - bioRxiv. 2021 Mar 24:2021.03.23.436684. doi: 10.1101/2021.03.23.436684 |
| References_xml | – year: 2021 ident: bib40 article-title: Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. Virological.org, https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592 – volume: 367 start-page: 1444 year: 2020 end-page: 1448 ident: bib79 article-title: Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 publication-title: Science – year: 2020 ident: bib53 article-title: Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection publication-title: bioRxiv – volume: 370 start-page: 1110 year: 2020 end-page: 1115 ident: bib3 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters publication-title: Science – volume: 166 start-page: 95 year: 2009 end-page: 102 ident: bib30 article-title: Appion: an integrated, database-driven pipeline to facilitate EM image processing publication-title: J. Struct. Biol. – volume: 369 start-page: 731 year: 2020 end-page: 736 ident: bib70 article-title: Broad neutralization of SARS-related viruses by human monoclonal antibodies publication-title: Science – volume: 183 start-page: 1043 year: 2020 end-page: 1057.e15 ident: bib12 article-title: SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 publication-title: Cell – volume: 383 start-page: 1920 year: 2020 end-page: 1931 ident: bib25 article-title: An mRNA Vaccine against SARS-CoV-2 - Preliminary Report publication-title: N. Engl. J. Med. – year: 2021 ident: bib16 article-title: Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant publication-title: medRxiv – year: 2021 ident: bib18 article-title: Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological.org – volume: 53 start-page: 98 year: 2020 end-page: 105.e5 ident: bib50 article-title: Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation publication-title: Immunity – volume: 151 start-page: 41 year: 2005 end-page: 60 ident: bib56 article-title: Automated molecular microscopy: the new Leginon system publication-title: J. Struct. Biol. – year: 2021 ident: bib62 article-title: Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data publication-title: medRxiv – volume: 591 start-page: 639 year: 2021 end-page: 644 ident: bib20 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature – volume: 180 start-page: 519 year: 2012 end-page: 530 ident: bib49 article-title: RELION: implementation of a Bayesian approach to cryo-EM structure determination publication-title: J. Struct. Biol. – volume: 32 start-page: 107918 year: 2020 ident: bib66 article-title: Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection publication-title: Cell Rep. – volume: 28 start-page: 516 year: 2020 end-page: 525.e5 ident: bib39 article-title: Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2 publication-title: Cell Host Microbe – volume: 184 start-page: 2332 year: 2021 end-page: 2347.e16 ident: bib34 article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 publication-title: Cell – volume: 397 start-page: 492 year: 2021 end-page: 495 ident: bib47 article-title: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence publication-title: Lancet – volume: 370 start-page: 950 year: 2020 end-page: 957 ident: bib60 article-title: Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms publication-title: Science – volume: 371 start-page: eabe6230 year: 2021 ident: bib28 article-title: Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape publication-title: Science – volume: 584 start-page: 120 year: 2020 end-page: 124 ident: bib51 article-title: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 publication-title: Nature – volume: 114 start-page: E7348 year: 2017 end-page: E7357 ident: bib41 article-title: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen publication-title: Proc. Natl. Acad. Sci. USA – volume: 13 start-page: 134 year: 2021 ident: bib19 article-title: Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies publication-title: Viruses – volume: 586 start-page: 583 year: 2020 end-page: 588 ident: bib36 article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques publication-title: Nature – volume: 369 start-page: 1586 year: 2020 end-page: 1592 ident: bib8 article-title: Distinct conformational states of SARS-CoV-2 spike protein publication-title: Science – volume: 41 start-page: 1006 year: 2020 end-page: 1022 ident: bib21 article-title: Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions publication-title: Trends Immunol. – volume: 384 start-page: 1468 year: 2021 end-page: 1470 ident: bib77 article-title: Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report publication-title: N. Engl. J. Med. – volume: 27 start-page: 622 year: 2021 end-page: 625 ident: bib72 article-title: SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma publication-title: Nat. Med. – volume: 21 start-page: 1327 year: 2020 end-page: 1335 ident: bib73 article-title: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function publication-title: Nat. Immunol. – volume: 369 start-page: 806 year: 2020 end-page: 811 ident: bib80 article-title: DNA vaccine protection against SARS-CoV-2 in rhesus macaques publication-title: Science – volume: 182 start-page: 828 year: 2020 end-page: 842.e16 ident: bib2 article-title: Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies publication-title: Cell – volume: 31 start-page: 107725 year: 2020 ident: bib33 article-title: Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections publication-title: Cell Rep. – volume: 94 year: 2020 ident: bib67 article-title: Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus publication-title: J. Virol. – volume: 584 start-page: 115 year: 2020 end-page: 119 ident: bib26 article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Nature – volume: 80 start-page: 9896 year: 2006 end-page: 9898 ident: bib5 article-title: Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium publication-title: J. Virol. – volume: 20 start-page: 533 year: 2020 end-page: 534 ident: bib15 article-title: An interactive web-based dashboard to track COVID-19 in real time publication-title: Lancet Infect. Dis. – volume: 218 start-page: e20201993 year: 2021 ident: bib48 article-title: Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo publication-title: J. Exp. Med. – year: 2020 ident: bib14 article-title: Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England publication-title: medRxiv – volume: 60 start-page: 2126 year: 2004 end-page: 2132 ident: bib17 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D Biol. Crystallogr. – volume: 179 start-page: 104820 year: 2020 ident: bib57 article-title: Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 publication-title: Antiviral Res. – volume: 369 start-page: 650 year: 2020 end-page: 655 ident: bib11 article-title: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 publication-title: Science – volume: 367 start-page: 1260 year: 2020 end-page: 1263 ident: bib75 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science – volume: 36 year: 2008 ident: bib6 article-title: IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis publication-title: Nucleic Acids Res. – year: 2020 ident: bib58 article-title: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa publication-title: medRxiv – volume: 384 start-page: 1466 year: 2021 end-page: 1468 ident: bib32 article-title: Neutralizing Activity of BNT162b2-Elicited Serum publication-title: N. Engl. J. Med. – volume: 584 start-page: 437 year: 2020 end-page: 442 ident: bib45 article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals publication-title: Nature – volume: 69 start-page: 140 year: 2020 end-page: 146 ident: bib42 article-title: Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020 publication-title: MMWR Morb. Mortal. Wkly. Rep. – volume: 12 start-page: 513 year: 2020 ident: bib13 article-title: Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays publication-title: Viruses – volume: 166 start-page: 205 year: 2009 end-page: 213 ident: bib63 article-title: DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy publication-title: J. Struct. Biol. – volume: 40 start-page: 658 year: 2007 end-page: 674 ident: bib35 article-title: Phaser crystallographic software publication-title: J. Appl. Cryst. – volume: 467 start-page: 591 year: 2010 end-page: 595 ident: bib82 article-title: Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation publication-title: Nature – volume: 11 start-page: 2251 year: 2020 ident: bib68 article-title: A human monoclonal antibody blocking SARS-CoV-2 infection publication-title: Nat. Commun. – volume: 93 start-page: 11382 year: 1996 end-page: 11388 ident: bib38 article-title: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector publication-title: Proc. Natl. Acad. Sci. USA – volume: 181 start-page: 281 year: 2020 end-page: 292.e6 ident: bib64 article-title: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein publication-title: Cell – year: 2020 ident: bib69 article-title: Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein publication-title: bioRxiv – volume: 109 start-page: E3268 year: 2012 end-page: E3277 ident: bib37 article-title: Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies publication-title: Proc. Natl. Acad. Sci. USA – volume: 369 start-page: 643 year: 2020 end-page: 650 ident: bib7 article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability publication-title: Science – volume: 182 start-page: 73 year: 2020 end-page: 84.e16 ident: bib9 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells publication-title: Cell – volume: 48 start-page: 799 year: 2018 end-page: 811.e9 ident: bib52 article-title: An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus publication-title: Immunity – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: bib65 article-title: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates publication-title: N. Engl. J. Med. – volume: 369 start-page: 956 year: 2020 end-page: 963 ident: bib46 article-title: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model publication-title: Science – volume: 372 start-page: 1413 year: 25 Jun 2021 end-page: 1418 ident: bib55 article-title: mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Science – volume: 29 start-page: 819 year: 2021 end-page: 833.e7 ident: bib10 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe – volume: 369 start-page: 1501 year: 2020 end-page: 1505 ident: bib23 article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes publication-title: Science – volume: 329 start-page: 112 year: 2008 end-page: 124 ident: bib59 article-title: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning publication-title: J. Immunol. Methods – volume: 384 start-page: 238 year: 2020 end-page: 251 ident: bib71 publication-title: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. – volume: 583 start-page: 290 year: 2020 end-page: 295 ident: bib43 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature – volume: 11 start-page: 5413 year: 2020 ident: bib24 article-title: Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation publication-title: Nat. Commun. – volume: 584 start-page: 450 year: 2020 end-page: 456 ident: bib31 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature – volume: 94 year: 2020 ident: bib61 article-title: Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures publication-title: J. Virol. – year: 2020 ident: bib44 article-title: Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological.org – volume: 66 start-page: 125 year: 2010 end-page: 132 ident: bib27 article-title: Xds publication-title: Acta Crystallogr. D Biol. Crystallogr. – volume: 182 start-page: 1663 year: 2020 end-page: 1673 ident: bib29 article-title: Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients publication-title: Cell – volume: 11 start-page: 53 year: 2004 end-page: 55 ident: bib1 article-title: Recent developments in the PHENIX software for automated crystallographic structure determination publication-title: J. Synchrotron Radiat. – volume: 181 start-page: 1004 year: 2020 end-page: 1015.e15 ident: bib74 article-title: Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies publication-title: Cell – volume: 27 start-page: 841 year: 2020 end-page: 848.e3 ident: bib78 article-title: An Infectious cDNA Clone of SARS-CoV-2 publication-title: Cell Host Microbe – volume: 584 start-page: 443 year: 2020 end-page: 449 ident: bib81 article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2 publication-title: Nature – volume: 181 start-page: 271 year: 2020 end-page: 280.e8 ident: bib22 article-title: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor publication-title: Cell – volume: 368 start-page: 1274 year: 2020 end-page: 1278 ident: bib76 article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 publication-title: Science – volume: 369 start-page: 1014 year: 2020 end-page: 1018 ident: bib4 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science – volume: 94 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib67 article-title: Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus publication-title: J. Virol. doi: 10.1128/JVI.00127-20 – volume: 29 start-page: 819 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib10 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – year: 2020 ident: 10.1016/j.celrep.2021.109353_bib14 article-title: Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England publication-title: medRxiv – year: 2020 ident: 10.1016/j.celrep.2021.109353_bib58 article-title: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa publication-title: medRxiv – volume: 94 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib61 article-title: Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures publication-title: J. Virol. doi: 10.1128/JVI.00985-20 – volume: 383 start-page: 1920 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib25 article-title: An mRNA Vaccine against SARS-CoV-2 - Preliminary Report publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022483 – volume: 40 start-page: 658 year: 2007 ident: 10.1016/j.celrep.2021.109353_bib35 article-title: Phaser crystallographic software publication-title: J. Appl. Cryst. doi: 10.1107/S0021889807021206 – year: 2020 ident: 10.1016/j.celrep.2021.109353_bib53 article-title: Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection publication-title: bioRxiv – volume: 383 start-page: 2439 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib65 article-title: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2027906 – volume: 11 start-page: 5413 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib24 article-title: Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation publication-title: Nat. Commun. doi: 10.1038/s41467-020-19231-9 – volume: 367 start-page: 1260 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib75 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science doi: 10.1126/science.abb2507 – volume: 184 start-page: 2332 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib34 article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 publication-title: Cell doi: 10.1016/j.cell.2021.03.028 – volume: 369 start-page: 806 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib80 article-title: DNA vaccine protection against SARS-CoV-2 in rhesus macaques publication-title: Science doi: 10.1126/science.abc6284 – volume: 32 start-page: 107918 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib66 article-title: Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107918 – volume: 584 start-page: 437 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib45 article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 182 start-page: 73 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib9 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 584 start-page: 443 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib81 article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2548-6 – year: 2021 ident: 10.1016/j.celrep.2021.109353_bib40 – year: 2020 ident: 10.1016/j.celrep.2021.109353_bib44 – volume: 182 start-page: 1663 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib29 article-title: Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients publication-title: Cell doi: 10.1016/j.cell.2020.08.046 – volume: 218 start-page: e20201993 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib48 article-title: Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo publication-title: J. Exp. Med. doi: 10.1084/jem.20201993 – volume: 584 start-page: 115 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib26 article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Nature doi: 10.1038/s41586-020-2380-z – volume: 397 start-page: 492 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib47 article-title: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence publication-title: Lancet doi: 10.1016/S0140-6736(21)00183-5 – volume: 36 year: 2008 ident: 10.1016/j.celrep.2021.109353_bib6 article-title: IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkn316 – volume: 179 start-page: 104820 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib57 article-title: Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2020.104820 – volume: 80 start-page: 9896 year: 2006 ident: 10.1016/j.celrep.2021.109353_bib5 article-title: Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium publication-title: J. Virol. doi: 10.1128/JVI.01118-06 – volume: 369 start-page: 643 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib7 article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability publication-title: Science doi: 10.1126/science.abc5902 – volume: 369 start-page: 650 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib11 article-title: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 publication-title: Science doi: 10.1126/science.abc6952 – volume: 66 start-page: 125 year: 2010 ident: 10.1016/j.celrep.2021.109353_bib27 article-title: Xds publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444909047337 – volume: 584 start-page: 450 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib31 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – year: 2021 ident: 10.1016/j.celrep.2021.109353_bib62 article-title: Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data publication-title: medRxiv – volume: 368 start-page: 1274 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib76 article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 publication-title: Science doi: 10.1126/science.abc2241 – volume: 181 start-page: 281 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib64 article-title: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 166 start-page: 95 year: 2009 ident: 10.1016/j.celrep.2021.109353_bib30 article-title: Appion: an integrated, database-driven pipeline to facilitate EM image processing publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2009.01.002 – volume: 13 start-page: 134 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib19 article-title: Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies publication-title: Viruses doi: 10.3390/v13010134 – year: 2020 ident: 10.1016/j.celrep.2021.109353_bib69 article-title: Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein publication-title: bioRxiv – volume: 369 start-page: 731 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib70 article-title: Broad neutralization of SARS-related viruses by human monoclonal antibodies publication-title: Science doi: 10.1126/science.abc7424 – volume: 584 start-page: 120 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib51 article-title: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2381-y – volume: 370 start-page: 1110 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib3 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters publication-title: Science doi: 10.1126/science.abe2402 – volume: 586 start-page: 583 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib36 article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-2607-z – volume: 183 start-page: 1043 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib12 article-title: SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 publication-title: Cell doi: 10.1016/j.cell.2020.09.033 – volume: 384 start-page: 1466 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib32 article-title: Neutralizing Activity of BNT162b2-Elicited Serum publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102017 – volume: 151 start-page: 41 year: 2005 ident: 10.1016/j.celrep.2021.109353_bib56 article-title: Automated molecular microscopy: the new Leginon system publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2005.03.010 – volume: 180 start-page: 519 year: 2012 ident: 10.1016/j.celrep.2021.109353_bib49 article-title: RELION: implementation of a Bayesian approach to cryo-EM structure determination publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2012.09.006 – volume: 369 start-page: 1014 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib4 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science doi: 10.1126/science.abd0831 – volume: 21 start-page: 1327 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib73 article-title: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0778-2 – volume: 11 start-page: 53 year: 2004 ident: 10.1016/j.celrep.2021.109353_bib1 article-title: Recent developments in the PHENIX software for automated crystallographic structure determination publication-title: J. Synchrotron Radiat. doi: 10.1107/S0909049503024130 – volume: 69 start-page: 140 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib42 article-title: Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6905e1 – volume: 27 start-page: 622 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib72 article-title: SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma publication-title: Nat. Med. doi: 10.1038/s41591-021-01285-x – volume: 60 start-page: 2126 year: 2004 ident: 10.1016/j.celrep.2021.109353_bib17 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444904019158 – volume: 369 start-page: 1501 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib23 article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes publication-title: Science doi: 10.1126/science.abd0826 – volume: 371 start-page: eabe6230 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib28 article-title: Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape publication-title: Science doi: 10.1126/science.abe6230 – volume: 181 start-page: 1004 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib74 article-title: Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies publication-title: Cell doi: 10.1016/j.cell.2020.04.031 – volume: 20 start-page: 533 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib15 article-title: An interactive web-based dashboard to track COVID-19 in real time publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30120-1 – volume: 12 start-page: 513 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib13 article-title: Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays publication-title: Viruses doi: 10.3390/v12050513 – volume: 93 start-page: 11382 year: 1996 ident: 10.1016/j.celrep.2021.109353_bib38 article-title: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.93.21.11382 – volume: 182 start-page: 828 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib2 article-title: Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies publication-title: Cell doi: 10.1016/j.cell.2020.06.025 – volume: 467 start-page: 591 year: 2010 ident: 10.1016/j.celrep.2021.109353_bib82 article-title: Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation publication-title: Nature doi: 10.1038/nature09385 – volume: 114 start-page: E7348 year: 2017 ident: 10.1016/j.celrep.2021.109353_bib41 article-title: Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1707304114 – volume: 27 start-page: 841 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib78 article-title: An Infectious cDNA Clone of SARS-CoV-2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.04.004 – year: 2021 ident: 10.1016/j.celrep.2021.109353_bib18 – volume: 181 start-page: 271 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib22 article-title: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 329 start-page: 112 year: 2008 ident: 10.1016/j.celrep.2021.109353_bib59 article-title: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2007.09.017 – volume: 384 start-page: 238 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib71 publication-title: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. – volume: 591 start-page: 639 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib20 article-title: Evolution of antibody immunity to SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03207-w – volume: 369 start-page: 1586 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib8 article-title: Distinct conformational states of SARS-CoV-2 spike protein publication-title: Science doi: 10.1126/science.abd4251 – volume: 109 start-page: E3268 year: 2012 ident: 10.1016/j.celrep.2021.109353_bib37 article-title: Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1217207109 – volume: 41 start-page: 1006 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib21 article-title: Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions publication-title: Trends Immunol. doi: 10.1016/j.it.2020.09.004 – volume: 583 start-page: 290 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib43 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature doi: 10.1038/s41586-020-2349-y – year: 2021 ident: 10.1016/j.celrep.2021.109353_bib16 article-title: Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant publication-title: medRxiv – volume: 369 start-page: 956 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib46 article-title: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model publication-title: Science doi: 10.1126/science.abc7520 – volume: 53 start-page: 98 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib50 article-title: Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation publication-title: Immunity doi: 10.1016/j.immuni.2020.06.001 – volume: 370 start-page: 950 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib60 article-title: Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms publication-title: Science doi: 10.1126/science.abe3354 – volume: 28 start-page: 516 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib39 article-title: Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.09.002 – volume: 372 start-page: 1413 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib55 article-title: mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Science doi: 10.1126/science.abg9175 – volume: 384 start-page: 1468 year: 2021 ident: 10.1016/j.celrep.2021.109353_bib77 article-title: Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102179 – volume: 11 start-page: 2251 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib68 article-title: A human monoclonal antibody blocking SARS-CoV-2 infection publication-title: Nat. Commun. doi: 10.1038/s41467-020-16256-y – volume: 166 start-page: 205 year: 2009 ident: 10.1016/j.celrep.2021.109353_bib63 article-title: DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2009.01.004 – volume: 31 start-page: 107725 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib33 article-title: Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107725 – volume: 48 start-page: 799 year: 2018 ident: 10.1016/j.celrep.2021.109353_bib52 article-title: An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus publication-title: Immunity doi: 10.1016/j.immuni.2018.03.026 – volume: 367 start-page: 1444 year: 2020 ident: 10.1016/j.celrep.2021.109353_bib79 article-title: Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 publication-title: Science doi: 10.1126/science.abb2762 – reference: 33791692 - bioRxiv. 2021 Mar 24:2021.03.23.436684. doi: 10.1101/2021.03.23.436684 |
| SSID | ssj0000601194 |
| Score | 2.5620155 |
| Snippet | SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development... |
| SourceID | doaj pubmedcentral osti proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 109353 |
| SubjectTerms | 60 APPLIED LIFE SCIENCES Angiotensin-Converting Enzyme 2 - chemistry Angiotensin-Converting Enzyme 2 - immunology Animals Antibodies, Monoclonal - immunology Antibodies, Neutralizing - immunology Antibodies, Viral - chemistry Antibodies, Viral - immunology B.1.351 Binding Sites Cell Line COVID-19 - immunology COVID-19 - prevention & control Cross Reactions CV3-25 Epitopes - immunology Female HEK293 Cells Humans Mice monoclonal antibodies neutralization Neutralization Tests NTD Protein Binding - immunology Protein Domains RBD S2 subunit SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - immunology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (WRLC) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ3fi9QwEMeDLAi-iL9dTyWCb1LcJG2SPurpcSeoL57cW0imKa4crexuBf3rnUnaZSvCvvjabbZNZpL5Npl8wthLZWwAS4RLsL5ABe4LG1ZNAa1WsFI2WKCNwh8_6fPL8sNVdXVw1BflhGU8cG64121ZyyaAiAQuq5X1JqIIr5oyigZ0FWn0xZh38DGVx2BimdGSspSUsyVLM-2bS8ldEK83kXCVUiSgUqVmcSnh-2fhadFjj_uXCv07mfIgOp3dYbdHWcnf5OrcZTdid4_dzAdN_rrP4AJdLNmA-67hsKc0502YvG95eq2ii0Oa-viNEY0D0Q38z_Vm2GKx3Tr0lHLIaUcKP_389eJdIepXfDsEmsvZPmCXZ--_nJ4X4_EKBWgpd0XjYwsgBZQmVMpgezVW65JoPysVtKxDNDrK2mOUrxPEpRG60cqjhowySvWQLbq-i48Zb4MBLYRqgfBkMdrS17U0wtOqdihXS6amxnUwssfpCIxrNyWZfXfZJI5M4rJJlqzYl_qR2RtH7n9LdtvfS-TsdAH9yY3-5I7505KZyepuFCFZXOBfrY88_oSchEoRfxcoUQmLoYSqUBgt2YvJdxz2YFqW8V3sh63DjzoCu-HQu2SPsi_tq0B8RoMKEN9q5mWzOs5_6dbfEiXcSqFRejz5H41ywm5RRWlOW6inbLHbDPEZirFdeJ763R-J4TAp priority: 102 providerName: Directory of Open Access Journals – databaseName: ScienceDirect Free and Delayed Access Titles dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3di9QwEMDDsSD4In5b7zwi-CZhN0mbpo_eesedoD7oyb6FJE21x9Eeu1tB__qbST-wIhz4uN2kbTKTzCSd-YWQNzLXzmskXHptGXjglmm3KpmvlPQrqZ32mCj88ZM6v0w_bLLNAVmPuTAYVjnM_f2cHmfr4cpy6M3lTV0vvwhYu4B1giVMxF8jE1SmOibxbU6mfRbkjfB4HiKWZ1hhzKCLYV4-XG8DgisFj2ilTM4sVAT5zwzVooWx9y9_9O-wyj_s1NlD8mBwMOm7vg2PyEFoHpN7_ZGTv54QfwHKFqVBbVNSP_Ga-3RM2lY0vhZrQhc3QX6DbaMeOQf2Z73tdlBtX7sWgw8p5qbQ9edvF-8ZL97SXedwV2f3lFyenX5dn7PhoAXmlRB7VtpQeS-4T3OXyRz6q9RKpcj9WUmnROFCroIoLNj7IuJcSq5KJS14k0EEIZ-RRdM24QWhlcu94lxWHkFlIejUFoXIucXv2y5dJUSOnWv8QCHHwzCuzRhudmV6kRgUielFkhA21brpKRx3lD9BuU1lkaEdL7Tb72ZQIlOlhSid5wGReIXUNg-wvMvKNPDSqywkJB-lbmYqCbeq73j8ISoJ1kISr8eQJagGzlQGLlJCXo-6Y2As4wca24S22xlY3iHiDSbhhDzvdWlqApIac_AF4a1mWjZr4_yfpv4ReeFacAVOyMv_bs8huY-_cEubyyOy2G-78Ap8sb07joPtFoNsMOQ priority: 102 providerName: Elsevier |
| Title | Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects |
| URI | https://dx.doi.org/10.1016/j.celrep.2021.109353 https://www.ncbi.nlm.nih.gov/pubmed/34237283 https://www.proquest.com/docview/2550260703 https://www.osti.gov/servlets/purl/1815023 https://pubmed.ncbi.nlm.nih.gov/PMC8216847 https://doaj.org/article/f492dbc1e9954938a7e8625d4e1dc65e |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fj5QwEG7ONZp7Mf4WTy-Y-GYw2xba8mCMd3q5NTl9cc2-NW0pumYDCovx_OudKbCKOXOJLzwAA21nhvlapt8Q8pRLZZ1ChkunTAII3CTKzovElYK7OVdWOdwofPZOnC7Tt6tstUfGmq3DALYXTu2wntSy2Tz_8e38JTj8i9-5Ws5vGo_sk4wGfqSMXyFXITZJLOZwNgD-_tuMHGfpuIfuH8L75DoS40mm-CRcBVb_SdSa1eCIF4HTv3Ms_whaJzfJjQFtxq9687hF9nx1m1zr60-e3yFuAZYXVBObqojdjry535sZ12UcmpVUvgsrIj8h0MUOSQ_M93XTtSC2XdsaMxFj3KgSH7__uHid0PxZ3HYWl3jau2R58ubD8WkyVF1InGBsmxTGl84x6lJpMy5huAolRIokQHNuBcutl8Kz3EDwzwO3S0FFIbgBaOmZZ_wemVV15R-QuLTSCUp56ZC1zHuVmjxnkhr82W3TeUT4OLjaDZTkWBljo8fcsy-6145G7eheOxFJdlJfe0qOS-4_Qr3t7kVC7XCibj7pwT91meassI565MfLuTLSw1wvK1JPCycyHxE5al0P2KTHHPCo9SWvP0AjQSmk5XWYvwRigKwywEsReTLajgbHxr81pvJ112qY6yHfG3yRI3K_t6VdF0brhFZNrGzSx-mVav05kIcrRgUgkof_LXlA9rF3uL5N-SMy2zadfwzAbGsPw4IGHBero8Pgd78A6X05pQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3db9MwEMCtUYTYC-KbMj6MxBuKWtuJ4zyywtTCNh7YUN8s23FG0JRMbTMJ_nrunA8RhDSJ1yTXxr6z7-zc_UzIW5Eq6xQSLp0yEUTgJlJ2nkeukMLNhbLKYaHwyalcnsef1sl6jyz6WhhMq-zm_nZOD7N1d2XW9ebsqixnXzmsXcA7wRIm4K_jW-Q2RAMSTXu1Phw2WhA4wsKBiCgQoURfQhfyvJy_3HgkV3IW2EqJGLmoQPIfeapJDYPvXwHp33mVfziqo_vkXhdh0vdtIx6QPV89JHfaMyd_PiJuBdYW1EFNlVM3AJvbekxaFzS8VlT5JuyC_ALnRh2CDsx1uWm2ILYrbY3ZhxSLU-jiy7fVh4hl7-i2sbits31Mzo8-ni2WUXfSQuQk57soN75wjjMXpzYRKfRXrqSMEfwzF1byzPpUep4ZcPhZ4LnkTOZSGAgnPfdcPCGTqq78M0ILmzrJmCgcksq8V7HJMp4ygx-4bTyfEtF3rnYdhhxPw7jUfb7ZD92qRKNKdKuSKYkGqasWw3HD84eot-FZhGiHC_XmQndWpIs447l1zCMTLxPKpB7Wd0kee5Y7mfgpSXut65FNwk-VN_z9ARoJSiGK12HOEohBNJVAjDQlb3rb0TCY8QuNqXzdbDWs75DxBrPwlDxtbWloAqIaUwgG4a1GVjZq4_hOVX4PwHDFmYQo5Pl_t-c1ubs8OznWx6vTzwdkH-_g_jYTL8hkt2n8SwjMdvZVGHi_Aeh1NAs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Isolation+and+characterization+of+cross-neutralizing+coronavirus+antibodies+from+COVID-19%2B+subjects&rft.jtitle=Cell+reports+%28Cambridge%29&rft.au=Jennewein%2C+Madeleine+F.&rft.au=MacCamy%2C+Anna+J.&rft.au=Akins%2C+Nicholas+R.&rft.au=Feng%2C+Junli&rft.date=2021-07-13&rft.pub=Cell+Press&rft.eissn=2211-1247&rft.volume=36&rft.issue=2&rft_id=info:doi/10.1016%2Fj.celrep.2021.109353&rft_id=info%3Apmid%2F34237283&rft.externalDocID=PMC8216847 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-1247&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-1247&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-1247&client=summon |